PCM
CHRS icon

Prelude Capital Management’s Coherus Oncology CHRS Stock Holding History

Prelude Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,436
Closed -$76K – 1615
2022
Q2 		$76K Sell
10,436
-1,036
-9% -$9.01K ﹤0.01% 1450
2022
Q1 		$148K Sell
11,472
-1,641
-13% -$20.9K ﹤0.01% 1337
2021
Q4 		$209K Sell
13,113
-1,314
-9% -$23K 0.01% 1544
2021
Q3 		$232K Sell
14,427
-327
-2% -$4.79K 0.01% 1279
2021
Q2 		$204K Sell
14,754
-946
-6% -$13.4K 0.01% 1369
2021
Q1 		$229K Buy
15,700
+4,600
+41% +$78.1K 0.01% 1266
2020
Q4 		$193K Hold
11,100
– – ﹤0.01% 1125
2020
Q3 		$204K Buy
11,100
+5,100
+85% +$94.9K 0.01% 688
2020
Q2 		$107K Buy
+6,000
New +$102K 0.01% 932
2017
Q3 		– Sell
-1,200
Closed -$17K – 1655
2017
Q2 		$17K Buy
1,200
+1,000
+500% +$19.2K ﹤0.01% 1295
2017
Q1 		$4K Sell
200
-3,100
-94% -$76.3K ﹤0.01% 1417
2016
Q4 		$93K Buy
3,300
+700
+27% +$19.6K 0.01% 858
2016
Q3 		$70K Sell
2,600
-300
-10% -$8.18K 0.01% 938
2016
Q2 		$49K Buy
2,900
+2,000
+222% +$37.5K 0.01% 1010
2016
Q1 		$19K Sell
900
-900
-50% -$14.7K ﹤0.01% 1118
2015
Q4 		$41K Sell
1,800
-200
-10% -$5.15K 0.01% 1080
2015
Q3 		$40K Sell
2,000
-500
-20% -$15.2K 0.01% 1112
2015
Q2 		$72K Buy
2,500
+1,800
+257% +$45.5K 0.01% 1016
2015
Q1 		$21K Sell
700
-800
-53% -$20.7K ﹤0.01% 1729
2014
Q4 		$24K Buy
+1,500
New +$21.2K ﹤0.01% 1677

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prelude Capital Management's CHRS Position: Q3 2022 in Review

Prelude Capital Management sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 10,436 shares — an estimated $76K sold.

Prelude Capital Management first reported a position in CHRS in Q4 2014 and held it in 20 quarters. The position peaked at $232K in Q3 2021. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • Prelude Capital Management reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 10,436 Coherus Oncology shares in Q3 2022, an estimated $76K.
  • Prelude Capital Management first reported a position in Coherus Oncology in Q4 2014 and held it in 20 quarters.
  • Prelude Capital Management's Coherus Oncology position peaked at $232K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.